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(DACRA), salmon calcitonin (sCT), was tested in three RAMP KO mouse models, RAMP1, RAMP3
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food intake and that the lack of AMY3 allowed sCT to be active. These results suggest that the chronic
use of DACRA such as sCT can have unfavourable effect on body weight loss in mice (which differs
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Abstract
The role of receptor activity-modifying proteins (RAMPs) in modulating the
pharmacological effects of an amylin receptor selective agonist (NN1213) or
the dual amylin–calcitonin receptor agonist (DACRA), salmon calcitonin
(sCT), was tested in three RAMP KO mouse models, RAMP1, RAMP3 and
RAMP1/3 KO. Male wild-type (WT) and knockout (KO) littermate mice were
fed a 45% high-fat diet for 20 weeks prior to the 3-week treatment period. A
decrease in body weight after NN1213 was observed in all WT mice, whereas
sCT had no effect. The absence of RAMP1 had no significant effect on NN1213
efficacy, and sCT was still inactive. However, the absence of RAMP3 impeded
NN1213 efficacy but improved sCT efficacy. Similar results were observed in
RAMP1/3 KO suggesting that the amylin receptor 3 (AMY3 = CTR
+ RAMP3) is necessary for NN1213’s maximal action on body weight and food
intake and that the lack of AMY3 allowed sCT to be active. These results sug-
gest that the chronic use of DACRA such as sCT can have unfavourable effect
on body weight loss in mice (which differs from the situation in rats), whereas
the use of the amylin receptor selective agonist does not. AMY3 seems to play
a crucial role in modulating the action of these two compounds, but in oppo-
site directions. The assessment of a long-term effect of amylin and DACRA in
different rodent models is necessary to understand potential physiological ben-
eficial and unfavourable effects on weight loss before its transition to clinical
trials.
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1 | INTRODUCTION
Currently, bariatric surgery is the most efficient approach
to treat obesity, but it is invasive, expensive and reserved
for patients who are critically obese (Peterli et al., 2018).
Thus, new therapy approaches to elicit body weight loss
need to be developed and a deeper understanding of the
underlying mechanisms that control food intake is
required (Andreassen et al., 2014; Larsen et al., 2020;
Mack et al., 2010; Soudy et al., 2017).
Amylin is a centrally acting peptide hormone
coproduced and cosecreted with insulin by pancreatic β
cells in response to nutrient influx in the gastrointestinal
tract (Bower & Hay, 2016; Cooper, 1994). Amylin’s main
site of action is located in the area postrema (AP) of the
caudal hindbrain (Boyle et al., 2018; Braegger et al., 2014;
Lutz et al., 2001). Pharmacologically, the desired effect of
amylin’s action is to decrease blood glucose and food
intake, associated with long-term body weight loss
(for review, see Hay et al., 2015). Amylin receptors com-
prise a calcitonin receptor core (Calcr/CTR a or b) com-
bined with one of the three receptor activity-modifying
proteins (RAMP1, 2 or 3). The CTR by itself shows more
affinity to calcitonin, but when associated with one of the
three RAMPs, producing AMY1, AMY2 and AMY3 (Hay
et al., 2018), these receptors present a higher affinity to
amylin (Garelja et al., 2018). CTR itself can reach the cell
surface, so it is likely that mixed populations of
CTR/RAMP complexes and CTR alone are found in the
different brain expression sites (Coester et al., 2020;
Liberini et al., 2016). In mice, CTR and RAMPs are
mostly expressed in the AP and at a lower level in the
nucleus of the solitary tract (NTS), in the lateral hypotha-
lamic area, in the ventromedial (VMH) and arcuate
(ARC) hypothalamic nuclei and in the ventral tegmental
area (Christopoulos et al., 1995; Christopoulos et al., 1999;
Coester et al., 2020; Husmann et al., 2000; Sexton
et al., 1986; Sexton et al., 1994). The AP contains a high
density of AMY (Lutz et al., 2001; Sexton et al., 1994), and
all the necessary components have been colocalized at the
single-cell level in the rat AP (Liberini et al., 2016) and
the mouse ARC (Coester et al., 2020).
Pramlintide, a human amylin analogue, is the only
amylin-based approved drug and is used in combination
with mealtime insulin to treat glucose excursions in
patients with type 1 and type 2 diabetes (Roth
et al., 2008; Weyer et al., 2001). Nevertheless, new amylin
receptor agonists with improved potency and pharmaco-
kinetics may provide better therapeutics for the treatment
of overweight and obesity.
This study aims to investigate the role of RAMPs in
mediating the subchronic pharmacological effects and
potential differences between the dual amylin–calcitonin
receptor agonist (DACRA), salmon calcitonin (sCT) (Hay
et al., 2015; Hay et al., 2018; Reidelberger et al., 2001;
Reidelberger et al., 2002), and an amylin selective
analogue, NN1213.
To assess the effects of sCT and NN1213, knockout
(KO) mouse models for a subunit of the amylin receptor
were used. RAMP1 KO, 3 KO and 1/3 KO mice allow us
to decipher the underlying mechanisms used by these
two peptides to decrease body weight. We have shown
previously that RAMPs KO mice are good models for the
study of amylin signalling (Coester et al., 2019) even
though they may present other metabolic alterations due
to the fact that RAMPs also affect the action of receptors
other than the amylin receptor (Boccia et al., 2020).
These mouse models have been extensively character-
ized, and we showed that acutely, amylin decreased food
intake in RAMP1 KO and sCT in RAMP3 KO only,
whereas RAMP1/3 KO mice were insensitive to both
peptides (Coester et al., 2019).
2 | MATERIAL AND METHODS
2.1 | Animals and husbandry
RAMP1 KO, RAMP3 KO and RAMP1/3 double KO mice
on a 129S2/SvEv background were kindly provided by
Kathleen Caron (University of North Carolina, USA).
RAMP1/3 KO are maintained on a KO breeding scheme,
whereas RAMP1 KO and 3 KO are bred by mating het-
erozygous mice. RAMP3 wild-type (WT) mice served as
WT control for the RAMP1/3 KO mice. Animals were
genotyped as previously published (Coester et al., 2019).
Male mice were housed in a controlled environment
maintained at 21  2C, under a 12-/12-h light–dark
cycle (lights off at 19.00 h). Mice had ad libitum access to
standard chow (Kliba 3436, 3.14 kcal/g of food) and
water, until 4–5 weeks old. Then mice were switched to
45% fat high-fat diet (HFD; D12451 Research Diets,
4.73 kcal/g of food, New Brunswick, NJ, USA) ad libitum
from approximately 4–5 to 24–25 weeks old. The same
diet was then continued during the 21-day treatment
period. The mice were group housed (2–3 mice per cage)
until 12 weeks old, when they had to be single-housed
due to aggressive behaviour and for food intake measure-
ments. Each cage was equipped with a red plastic house
and nest-building material and wood shavings. Prior to
the 21-day treatment, mice were injected with vehicle for
1 week to acclimate to the daily subcutaneous injections
to reduce stress.
All animal experimental protocols in this study were
approved by the University of Zurich Animal Protection
Office and Ethics committee, the Veterinary Office of the
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Canton of Zurich, and conform to Swiss Animal
Protection guidelines and regulations (Swiss Animal
Protection and Swiss Animal Act and Ordinance) and in
accordance with the EU Directive on the protection of
animals used for scientific purposes. These studies adhere
to the ARRIVE guidelines.
2.2 | Genotyping
Briefly, DNA was extracted from toe biopsies: 200 μl of
50-mM NaOH was added, heated at 95C and shaken at
800 rpm for 35 min; samples were then neutralized with
200 μl of 500-mM Tris–HCl, pH 5.5. One microliter of
DNA was then combined by the respective primers, and
GoTaq polymerase was used (Promega A6001). Animals
were genotyped using the following primers: RAMP1 for-
ward TCATGGGGACCTTTAGGTAAGC, RAMP1 reverse
ACAGCAATCCTTCT ACCTCAACAC, RAMP3 WT
band is detected using R3–1: GTGCTCAAGGGTTCTG
TCTG and R3–10: GACCTGGTTCATCTCTGGCTCC and
RAMP3 null band is detected using R3–10: GACCTGG
TTCATCTCTGGCTCC and neo-60: GCTTCCTCTTG
CAAAACCACA (Dackor et al., 2007).
2.3 | Food intake, body weight and non-
fasted blood glucose level during 20 weeks
on 45% HFD
Weekly body weight and food intake were measured
manually. Blood was harvested from the tail, and non-
fasted glucose was measured using Contour Next Blood
Glucose Meter (Bayer Consumer Care AG, Basel,
Switzerland) every 2 weeks at 14.00 h, that is, in the sec-
ond half of the light phase.
2.4 | Peptides
All experimental drugs were provided by Novo
Nordisk Pharma AG. Vehicle: 5-mM acetate, 249-nM
propylene glycol, 0.007% Tween 20; NNC0174-1213
(NN1213): 5 nmol/ml, 30 nmol/kg; sCT 0186:
27.7 nmol/ml, 150 nmol/kg. The structural description of
NN1213 (= AM1213) is presented in Figure 1a.
2.5 | BacMam receptor expression and
cAMP potency assay
HeLa cells were grown in DMEM supplemented with
glucose, sodium pyruvate, GlutaMax™ and phenol red,
10% fetal calf serum and 1% penicillin/streptomycin
(ThermoFisher Scientific). The BacMam system (Life
Technologies) was used to transduce the HeLa cells
with the mouse CTRb family receptors. Recombinant
mouse CTRb or the respective AMY1–3b receptors
expressing cells were plated to a density of 3  105
cell/ml in medium containing either mCTRb (1% v/v)
alone or mCTRb (1% v/v) with one of the three RAMPs
(15% v/v) and cultured at 37C, 5% CO2 and 95% rela-
tive humidity. To determine potencies, the cells were
stimulated with NN1213, sCT or rat/mouse amylin.
Stimulation of CT family receptors activates adenylyl
cyclase, leading to accumulation of cyclic AMP (cAMP)
when 3-isobutyl-1-methylxanthine (IBMX) is added.
Increasing levels of endogenous cAMP were measured
F I GURE 1 Peptide amino acid structure
and 24-h food intake in chow-fed C57Bl6 male
mice in response three doses of NN1213 and
salmon calcitonin (sCT). (a) Amino acid
structure of rat amylin, NN1213 and sCT;
(b) 24-h cumulative food intake after NN1213
s.c. injection; (c) 24-h cumulative food intake
after sCT s.c. injection. The grey area represents
the dark phase. Data are expressed as
mean  SEM, N = 8/group. Statistics: two-way
analysis of variance (ANOVA) with repeated
measured followed by Tukey post hoc
comparison; **P < 0.01; Rx: treatment
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as a reduction in fluorescence resonance energy transfer
(FRET) between Europium (Eu3+)–cryptate-conjugated
anti-cAMP antibody and d2-conjugated cAMP. The
fluorescence ratio was plotted as a function of the
concentration of compound (cAMP HTRF® Assay kit,
Cisbio). Data were analysed in GraphPad Prism 7, and
EC50 values were calculated by nonlinear regression
analysis of sigmoidal dose response curves. Mean
pEC50 with the 95% confidence interval are shown in
Figure S1.
2.6 | Acute food intake dose response
study in C57BL/6J male mice
C57BL/6J male mice (n = 8, Taconic, Germany, 10 weeks
of age) were housed in the BioDAQ cages (Research
Diets, Inc, New Brunswick, NJ, USA) to continuously
monitor their food intake over a 24-h period. After a
week of adaptation to new environment and a standard
low fat diet (D12450B, Research Diets Inc), a 24-h
baseline food intake measurement was performed before
study initiation, and mice were fasted for 4 h before
dosing. Mice were dosed subcutaneously (<20 min) prior
to the onset of the dark cycle, with a single SC injection
with three doses of sCT (75, 150 and 300 nmol/kg), three
doses of NN1213 (10, 30 and 100 nmol/kg) or
vehicle, resp.
2.7 | Mouse subchronic treatment
At the age of 24–25 weeks and after 20 weeks on 45%
HFD, male RAMP1/3 KO, RAMP1 KO and RAMP3
KO mice and their respective WT littermates were
randomized by body weight and assigned to their
treatment group (n = 8/group): vehicle; NN1213
(30 nmol/kg/d); sCT (150 nmol/kg/d). Mice were injected
subcutaneously once a day for 3 weeks in the middle of
the light phase between 11.00 and 12.00 h. Prior to
injection, daily body weight and food intake were
measured manually.
2.8 | Sacrifice
On the day of sacrifice, mice were fasted for 2 h during
the light phase and sacrificed under pentobarbital anaes-
thesia (100 mg/kg, IP injection, Cantonal Pharmacy of
Zurich, Switzerland). Blood was sampled using cardiac
puncture, and brains were harvested and frozen on dry
ice. The mice were stored at 20C until body composi-
tion analysis was performed.
2.9 | Measurement of body composition
Quantitative microcomputed tomography of WT mice
and RAMP1/3 KO mice was performed using La Theta
LCT-100A (LaTheta LCT-100A scanner, Hitachi-Aloka
Medical Ltd., Tokyo, Japan) on the carcasses of the ani-
mals placed supine in the plexiglass holder after sacrifice
(Coester et al., 2019; Senn et al., 2019). The region
between the vertebrae L1–L6 was evaluated for lean and
fat mass. Although the software LaTheta already auto-
matically distinguished between visceral and subcutane-
ous fat, each image was manually examined, and in some
cases, an image-by-image correction was required.
Adipose tissue weights were then computed using the
commonly used density factor of 0.92 g/cm3 to determine
the absolute values in gram (Bray, 1999).
2.10 | Biochemical analysis
Blood samples were collected from the right ventricle of
the heart during the sacrifice in 1-ml EDTA-coated tubes
containing DPP4 inhibitor (10 μl/ml blood) and protein-
ase inhibitor (P2414; Sigma Aldrich, 30 μl/ml blood).
After centrifugation, plasma was kept at 80C. Plasma
levels of leptin and insulin were measured with a Mouse
Metabolic Biomarkers kit (MesoScale Discovery,
Gaithersburg, MD, USA).
2.11 | Statistical analysis
All analyses were performed using GraphPad Prism
software version 8.0 (GraphPad, San Diego, CA). In
experiments comparing independent treatment groups,
significance was tested using one-way analysis of variance
(ANOVA). When more than one factor was compared,
two-way ANOVA was performed, followed by Sidak or
Tukey’s multiple comparisons test as recommended. A
P value of <0.05 was considered statistically significant.
All data are presented as mean  SEM.
3 | RESULTS
3.1 | Efficacy of NN1213 compared with
that of sCT at the mCTR compared
to AMYs
NN1213 and mouse amylin showed decreased affinity to
mCTR compared with sCT (Figure S1a). However, at the
level of the amylin receptor AMY1, NN1213 and amylin
showed increased potency compared with mCTR alone.
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Overall, NN1213 is more potent than amylin but less
potent than sCT (Figure S1b–d). The potency of NN1213
and amylin was lower at the AMY2 and AMY3 than at
the AMY1 (P < 0.001, Figure S1c,d). Thus, these results
confirm that NN1213 is an amylin receptor agonist
whereas sCT is a DACRA.
3.2 | Acute food intake dose response
study in mice
Ten-week-old C57BL/6J mice were tested for their food
intake response to single injections of increasing doses of
sCT and NN1213 (Figure 1b,c). All doses of NN1213 and
sCT decreased food intake compared with vehicle,
and no statistical difference was observed among the
three doses. The doses of 30 and 150 nmol/kg of NN1213
and sCT, respectively, were chosen because they
suppressed food intake to a similar extent at 24 h.
3.3 | 20 weeks of 45% HFD feeding in
RAMP1/3 KO, 1 KO, 3 KO and WT mice
From 4 to 24 weeks old, WT and RAMP1/3 KO
mice body weight and food intake on 45% HFD were
followed weekly (Figure S2). Baseline body weight was
similar across both groups with no significant difference
at the start of the experiment (Figure S2a). From Week
8 onward, RAMP1/3 KO mice displayed a significantly
lower body weight (P < 0.001; Figure S2a) and gained
27% less weight over the 20-week period (P < 0.001;
Figure S2d) compared with the WT cohort. The higher
body weight gain in the WT mice is consistent with a 10%
increase in cumulative food intake (P < 0.001;
Figure S2g) and a 30% increase of blood glucose level
compared to RAMP1/3 KO mice (P < 0.001; Figure S2j).
In RAMP3 WT and KO mice, baseline body weight
average was similar at the beginning of the study
(Figure S2b). After 20 weeks on HFD, no difference in
body weight (Figure S2b), body weight gain (Figure S2e)
or food intake (Figure S2h) was observed between WT
and RAMP3 KO littermates. However, biweekly tail
blood glucose was temporarily increased by 26% and 20%
in RAMP3 KO mice at Weeks 14 and 16, respectively,
compared with RAMP3 WT mice (P < 0.05; Figure S2k).
As for the RAMP1 KO, no significant difference during
the HFD period was observed, with exception of Week
16, where RAMP1 WT mice showed a significantly higher
body weight compared with the KO (Figure S2c).
Similarly to the RAMP3 KO, 45% HFD had the same
effect on body weight gain in WT and RAMP1 KO mice
throughout the entire HFD period (Figure S2f). However,
food intake was significantly increased by 10% in RAMP1
WT (P < 0.001; Figure S2i), whereas no significant differ-
ence in blood glucose level was detected between both
genotypes (Figure S2l). Overall, RAMP1 KO/WT mice
gained less weight and ate less over the 20 weeks of HFD
than RAMP3 KO/WT mice (Strain P < 0.0001;
Figure S2e,f,h,i), but food intake was similar to that of
RAMP1/3 KO.
3.4 | Efficacy of the DACRA sCT in
RAMP3 KO mice whereas the amylin-
selective agonist NN1213 is efficient in WT
but not in RAMP3 KO mice
Baseline body weight was not significantly different at
the start of the injection period (Figure 2a) and body
weight remained similar among the groups during the
treatment period (Figure 2a). Body weight gain decreased
by 7% in NN1213-treated RAMP3 WT mice relative
to vehicle-treated RAMP3 WT controls (%P < 0.05;
Figure 2b,c). RAMP3 KO mice also responded to NN1213
but not to the same extent as WT mice during the first
2 weeks, and at the end of the study, the two groups
displayed the same body weight loss (Figure 2b,c). Simi-
lar to RAMP1/3 KO (Figure 4), a marked decrease in
body weight gain was observed in RAMP3 KO mice
treated with sCT between Day 3 and Day 14 (ΧP < 0.05;
Figure 2b,c) but not in RAMP3 WT mice. At the conclu-
sion of the study, the effect of sCT in RAMP3 KO mice
was not significantly different from WT and KO
mice treated with the amylin-selective agonist NN1213,
but the initial drop in body weight gain was more
marked, more rapid and longer lasting with sCT in KO
mice. Overall, a decrease in body weight gain in
response to NN1213 was observed in RAMP3 WT mice
during the first 2 weeks of treatment whereas RAMP3
KO mice responded to sCT (Figure 2b,c). No significant
difference in food intake between the groups was
observed (Figure 2d). At the time of sacrifice, blood
glucose levels were similar regardless of genotype or
treatment (Figure 2e). Thus, the absence of RAMP3
impedes NN1213 efficacy and improves sCT weight
loss efficacy.
3.5 | Efficacy of the amylin-selective
agonist NN1213 in WT and RAMP1 KO
mice whereas sCT has no effect in both
strains
During the first week of treatment, RAMP1 WT and KO
treated with NN1213 similarly responded to the
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treatment and gained 7% less weight, compared with
their respective vehicle-treated group (%, βP < 0.05;
Figure 3b,c). In the second and third week of treatment,
NN1213-treated RAMP1 WT and KO mice maintained
their reduced body weight loss in comparison with the
vehicle control group. No difference in NN1213 weight
loss efficacy is observed between WT and RAMP1 KO
mice when subtracting from their respective vehicle-
treated group (Figure 3c). In contrast, sCT had no effect
in RAMP1 WT and KO mice (Figure 3b,c). Starting at
Day 14 of treatment, cumulative food intake was signifi-
cantly increased by 22% and 15% in sCT-treated WT and
KO compared with their respective NN1213-treated
group, and this difference remained significant until the
end of the treatment period (Δ, ΠP < 0.05; Figure 3c). No
genotype or treatment effect on blood glucose level was
observed at sacrifice (Figure 3d).
Because starting body weight was much lower in
RAMP1 WT/KO mice compared with the RAMP3 strain
(Figures S2c and S3a), nasal–anal length of RAMP1 and
RAMP3 mice at the end of the treatment period was
measured. Overall, RAMP1 WT and KO mice were signif-
icantly shorter than RAMP3 WT and KO mice (data not
shown). Thus, the absence of RAMP1 had no significant
effect on NN1213 efficacy and did not restore sCT
efficacy.
F I GURE 2 Effect of amylin-selective agonist NN1213 (30 nmol/kg) and sCT (150 nmol/kg) subchronic treatment (21 days) in receptor
activity-modifying protein (RAMP) 3 wild-type (WT) and knockout (KO) mice after an induction obesity period of 20 weeks on 45% HFD.
(a) Daily body weight (g) of RAMP3 WT and KO mice treated for 21 days with vehicle, NN1213 (30 nmol/kg) and salmon calcitonin (sCT)
(150 nmol/kg); (b) daily body weight gain (g); (c) body weight gain subtracted from respective vehicle group (g); (d) daily food intake;
(e) glucose (mmol/L) at sacrifice. Data are presented as mean  SEM; number of mice per group WT + veh = 8; WT + NN1213 = 8; WT
+ sCT = 7; RAMP3 KO + veh = 8; RAMP3 KO + NN1213 = 8; RAMP3 KO + sCT = 7. Statistics: two-way analysis of variance (ANOVA)
with repeated measured followed by Tukey post hoc comparison; %P < 0.05 WT + veh versus WT + NN1213, ΔP < 0.05 WT + NN1213
versus WT + sCT, *P < 0.05 WT + sCT versus RAMP3 KO + sCT, ΧP < 0.05 RAMP3 KO + veh versus RAMP3 KO + sCT, ΠP < 0.05
RAMP3 KO + sCT versus RAMP3 KO + NN1213
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3.6 | DACRA sCT decreases body weight
in RAMP1/3 KO mice whereas the amylin-
selective agonist NN1213 does not
WT and double RAMP1/3 KO animals had a significantly
different baseline body weight, and this difference in
body weight remained significant until the end of the
treatment period (Figure 4a). From Day 3 to Day
8, RAMP1/3 WT injected with the amylin-selective
agonist NN1213 showed a 5% weight loss compared with
vehicle treated mice (%P < 0.05; Figure 4b,c); Figure 4c
indicates the body weight gain subtracted from respective
vehicle group. After this initial effect, RAMP1/3 WT
NN1213-treated mice regained weight until the end of
the treatment period (Figure 4b), but if compared with
vehicle-injected group, this weight loss was maintained
(Figure 4c). In comparison, NN1213 had no significant
effect in RAMP1/3 KO mice on body weight in the first
days, and mice continued to gain weight as did the
vehicle control RAMP1/3 KO mice (Figure 4a–c). sCT
decreased WT mice body weight gain by 2% during the
first 2 days (P = 0.03 vs. vehicle WT), and this was
followed by weight regain similar to vehicle-treated mice.
Conversely, sCT-treated RAMP1/3 KO mice progressively
lost weight and reached a maximum 5% weight loss on
day 10 (ΧP < 0.05; Figure 4b,c), which was followed
by some weight regain, but the two sCT-treated
groups remained significantly different throughout the
F I GURE 3 Effect of amylin-selective agonist NN1213 (30 nmol/kg) and salmon calcitonin (sCT) (150 nmol/kg) subchronic treatment
SC (21 days) in receptor activity-modifying protein (RAMP) 1 wild-type (WT) and knockout (KO) mice after an induction obesity period of
20 weeks on 45% HFD. (a) Daily body weight (g) of RAMP1 WT and KO mice treated for 21 days with vehicle, NN1213 (30 nmol/kg) and
sCT (150 nmol/kg); (b) daily body weight gain (g); (c) body weight gain subtracted from respective vehicle group (g); (d) daily food intake;
(e) glucose (mmol/L) at sacrifice. Data are presented as mean  SEM; number of mice per group WT + veh = 9; WT + NN1213 = 9; WT
+ sCT = 9; RAMP3 KO + veh = 8; RAMP1 KO + NN1213 = 7; RAMP1 KO + sCT = 9. Statistics: two-way analysis of variance (ANOVA)
with repeated measured followed by Tukey post hoc comparison; %P < 0.05 WT + veh versus WT + NN1213, βP < 0.05 RAMP1 KO + veh
versus RAMP1 KO + NN1213, ΧP < 0.05 RAMP1 KO + veh versus RAMP1 KO + sCT, ΠP < 0.05 RAMP1 KO + sCT versus RAMP1 KO
+ NN1213
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F I GURE 4 Effect of amylin-selective agonist NN1213 (30 nmol/kg) and salmon calcitonin (sCT) (150 nmol/kg) subchronic treatment
for 21 days in receptor activity-modifying protein (RAMP) 1/3 wild-type (WT) and knockout (KO) mice after an induction obesity period of
20 weeks on 45% HFD. (a) Daily body weight (g) of RAMP1/3 WT and KO mice treated for 21 days with vehicle, NN1213 (30 nmol/kg) and
sCT (150 nmol/kg); (b) daily body weight gain (g); (c) bodyweight gain subtracted from respective vehicle group (g) which was set to 0;
(d) daily food intake; (e) weekly food intake; (f–h) glucose (mmol/L), insulin (pg/ml) and leptin (pg/ml) concentration measured in plasma
of RAMP1/3 WT and KO mice at time of sacrifice. Data are presented as mean  SEM; number of mice per group WT + veh = 8; WT
+ NN1213 = 8; WT + sCT = 7; RAMP1 KO + veh = 8; RAMP1 KO + NN1213 = 8; RAMP1 KO + sCT = 7. Statistics: two-way analysis of
variance (ANOVA) with repeated measured followed by Tukey post hoc comparison; (a–c): %P < 0.05 WT + veh versus WT + NN1213,
*P < 0.05 WT + sCT versus RAMP1/3 KO + sCT, &P < 0.05 WT + NN1213 versus RAMP1/3 KO + NN1213, ΧP < 0.05 RAMP1/3 KO + veh
versus RAMP1/3 KO + sCT, ΠP < 0.05 RAMP3 KO + sCT versus RAMP3 KO + NN1213. (f–h) *Symbols denote significant differences
between the two genotypes; *P < 0.05, **P < 0.01. (d, e, h) Parameters with differing letters (a, b) differ from each other by P < 0.05 after
two-way ANOVA (group, time) followed by Tukey post hoc test
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21 days (*P < 0.05; Figure 4b,c); hence, sCT produced
lasting weight loss in the RAMP1/3 KO but not in the
WT mice.
For the entire duration of the experiment, cumulative
food intake as well as weekly food intake was signifi-
cantly lower in RAMP1/3 KO mice treated with NN1213
than the other groups, which ate a similar amount of
food during the treatment period (Figure 4d,e). Thus,
even though NN1213-treated RAMP1/3KO mice did not
significantly decrease their body weight, food intake was
decreased.
No effect of sCT or NN1213 on blood glucose levels
was observed between the two genotypes. However,
RAMP1/3 KO mice displayed lower glucose levels than
WT mice (P < 0.0001, F[1, 40] = 22.18; Figure 4f) and
insulin (P = 0.03, F[1, 38] = 4.617; Figure 4g). This
genotype effect may result from the lower body weight
displayed by RAMP1/3 KO mice compared with WT
mice (*P < 0.05; Figure 4a). NN1213-treated WT mice
showed a 60% decrease in leptin plasma concentration
compared with WT-vehicle mice (Figure 4h). RAMP1/3
KO mice displayed significantly lower leptin levels
compared with WT mice treated with vehicle
(Figure 4h) and were similar to that of WT NN1213
mice. sCT-treated RAMP1/3 KO also displayed a 48%
decrease in visceral fat mass compared to sCT-treated
WT mice (P < 0.05; Table 1). Lean mass was
significantly decreased by 23% in RAMP1/3 KO mice
compared with the WT cohort (Table 1), regardless of
the treatment received, which reflects their lower body
weight in general (P < 0.0001, F[1, 40] = 21.06;
Figures S2a and 4a).
3.7 | Distribution of CTR, RAMP1,
RAMP2 and RAMP3 in the AP and NTS of
vehicle-treated WT, RAMP1 KO, RAMP3
KO and RAMP1/3 KO HFD-fed mice
An exploratory staining was performed in the four mouse
models to assess the expression of CTR and the three
RAMPs in the AP and NTS of these mice and test
whether the KO of one or two RAMPs affects the mRNA
expression of CTR and the other RAMPs.
In WT mice, CTR is colocalized at the mRNA level
with all the three RAMPs in one cell as indicated by the
full arrows (Figure S3a–d), and RAMPs are also present
in AP cells without CTR (Figure S3d). Although CTR
seems to be always colocalized with RAMP in the AP
(Figure S3c), this is not the case in the NTS (Figure S3a,
b). Furthermore, RAMP2 seems to be the preferentially
colocalized RAMP with CTR in the AP (Figure S3d).
Interestingly, when RAMP1 or RAMP3 is absent, it
decreases the transcription of other RAMPs and of CTR
in the AP and NTS (Figure S3e–p). In particular, in the
absence of RAMP3, RAMP2 and RAMP1 are highly
colocalized within the same cells but not with CTR
(Figure S3i–l). Furthermore, in RAMP1/3 KO mice, the
depletion of RAMP1 and RAMP3 decreased the transcrip-
tion of RAMP2 and prevented its colocalization with
CTR. Thus, the depletion of RAMP3 may prevent the
colocalization of CTR with RAMP1 or RAMP2, but this is
not the case in RAMP1 KO mice (Figure S3e–h). There-
fore, these data might suggest a transcriptional regulation
of CTR and RAMP by its endogenous ligands and by
RAMP3. Whether the protein expression reflects what we
TAB L E 1 Body composition in g or as percent of body weight (% BW) in RAMP1/3 WT and KO injected with vehicle, NN1213 and sCT
for 21 days after 20 weeks on 45% HFD
WT + vehicle WT + NN1213 WT + sCT 1/3 KO + vehicle 1/3 KO + NN1213 1/3 KO + sCT
Lean 7.13  0.55a 6.61  0.38a,b 7.41  0.48a,b 5.52  0.21b 5.26  0.21b 5.56  0.22b
Lean % BW 15.6  1.06 15.5  1.19 16.1  0.63 16  0.68 15.7  1.09 15.8  0.81
Visceral fat 3.89  0.64a,b 3.39  0.6a,b 4.10  0.50a 2.7  0.28a,b 2.89  0.34a,b 2.12  0.17b
Visceral fat
(% BW)
8.2  0.77 7.4  1.13 8.6  0.68 7.74  0.69 8.31  0.7 5.97  0.37
Subcutaneous fat 2.10  0.23 1.72  0.32 1.77  0.28 1.76  0.2 1.75  0.23 1.67  0.17
Subcutaneous fat
(% BW)
4.6  0.43 3.7  0.6 3.7  0.5 5.03  0.45 5.04  0.45 4.71  0.43
Total fat 5.99  0.85 5.11  0.9 5.87  0.71 4.46  0.43 4.64  0.55 3.79  0.31
Total fat (% BW) 12.8  1.06 11.1  1.65 12.3  0.98 12.7  0.96 13.3  1.07 10.7  0.69
Fat ratio (%) 44.9  3.66 41.1  5.71 43.7  2.48 44.2  2.7 45.9  3.2 40.3  2.6
Note: Data are presented as mean  SEM; N = 8/group. For each row, groups with differing superscript letters differ from each other at P < 0.05 level by
Tukey post hoc adjustment after significant intergroup differences were found by two-way ANOVA.
Abbreviations: HFD, high-fat diet; KO, knockout; sCT, salmon calcitonin;WT, wild type.
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observed at the mRNA level still remains to be
determined.
4 | DISCUSSION
The aim of this study was to assess the weight loss effi-
cacy of the amylin selective agonist (NNC0174-1213) in
the three RAMP KO mouse models compared with that
of DACRA sCT and to investigate the role of RAMPs in
modulating the pharmacological effects and potential
differences on body weight and food intake in response
to the treatment. We first observed that in WT mice,
subchronic sCT does not have any sustained effect on
body weight and food intake whereas the amylin agonist
NN1213 was able to decrease body weight and to tran-
siently decrease food intake. Second, NN1213 partially
decreased body weight in RAMP1 KO mice, but not in
RAMP3 and RAMP1/3 KO mice suggesting the necessity
of AMY3 for NN1213 body weight loss efficacy. Third,
sCT lowered body weight gain in RAMP1/3 and RAMP3
KO mice but not in WT and RAMP1 KO mice suggesting
that the DACRA’s effects on body weight during
subchronic administration is hindered by the presence
RAMP3 (Table S1).
The subchronic treatment clearly demonstrates that
WT mice are sensitive to NN1213 by decreasing their
body weight which is accompanied by a moderate ano-
rectic effect. The effect of NN1213 is stronger in the first
5 days of treatment and is followed by a stabilization
period where the mice maintained their body weight loss.
On the contrary, and different from the effect in lean or
HFD-fed rats (Andreassen et al., 2014; Feigh et al., 2011;
Feigh et al., 2012; Gydesen et al., 2016; Hjuler
et al., 2015; Larsen et al., 2020), the DACRA sCT had a
minimal effect in the different WT mice. WT mice dis-
played no change in insulin and leptin when treated with
sCT, while NN1213 decreased leptin levels. Interestingly,
even though total body fat mass analysis is not different
between WT groups, visceral fat is decreased in
NN1213-treated WT mice compared with vehicle and
sCT-treated WT mice. Given the lower leptin levels, it is
possible that we may have missed a decrease in subcuta-
neous fat pads because we only quantified fat mass from
L1 to L6. The first main conclusion of this study is that
subchronic sCT treatment, different from rats, even at a
relatively high dose (150 nmol/kg) does not have any
effect in WT mice whereas the amylin agonist NN1213 at
a dose of 30 nmol/kg is able to elicit body weight loss by
decreasing fat mass in mice.
To examine the contribution of each RAMP in the
response to sCT and NN1213, single and double KO mice
were tested. NN1213 produced a body weight loss in
RAMP1 KO, whereas in RAMP3 KO and RAMP1/3 KO,
it had no effect. This suggests that the presence of AMY3
is necessary to mediate the effect of NN1213. Conversely,
sCT induced body weight loss in both RAMP1/3 double
KO (5%) and RAMP3 KO (8%) mice but no sustained
effect in the RAMP1 KO mice. Thus, we may hypothesize
that the presence of AMY3 impedes sCT’s body weight
loss efficacy in mice during subchronic administration.
To explain this effect of DACRA in the absence of
RAMP3, we have previously shown that, in C57Bl6 mice,
CTRa seems to be preferentially colocalized with RAMP3
compared with RAMP1 in the AP (Coester et al., 2020);
thus, we may hypothesize that in the absence of RAMP3,
CTR is available and preferentially binds sCT. Using in
situ hybridization, we here showed that in absence of
RAMP3, CTR is less colocalized with the remaining
RAMPs. More studies at the pharmacological levels are
however needed to understand why AMY3 prevents the
subchronic action of sCT in mice but not in rats,
and why WT mice do respond to sCT after acute
administration.
These current studies highlight the species-specific
effects of DACRA. Opposite to mice, several studies have
demonstrated that sCT or other DACRA compounds are
able to induce long-term weight loss in diet induced
obese rats (Andreassen et al., 2014; Feigh et al., 2011;
Feigh et al., 2012; Gydesen et al., 2016; Hjuler
et al., 2015; Larsen et al., 2020). Rats treated sub-
chronically with one of the above-mentioned peptides
lost weight and transiently reduced their food intake in a
dose-dependent manner. For example, rats treated with
KBP-089 showed a body weight loss of 17% and presented
a reduction in fat depots and fat accumulation in liver
and in muscles (Gydesen, Andreassen et al., 2017;
Gydesen, Hjuler et al., 2017). Two other DACRAs from
the same company, KBP-088 and KBP-042, were also able
to reduce body weight when injected or given orally in a
sustained and dose-dependent manner; additionally, they
reduced white adipose tissue mass and adiposity
hypertrophy (Andreassen et al., 2014; Hjuler et al., 2015;
Srivastava & Apovian, 2018). These KBP compounds
were unfortunately not tested in HFD-fed mice
preventing us to make a comparison with our current
study.
The reason for this species difference in sCT’s and
DACRA’s actions remains unknown. So far, no basic dif-
ferences between the roles of RAMPs and the different
CTR subtypes in mice versus rats have been reported. We
could hypothesize that RAMP1–3 distribution may differ
between mice and rats and because sCT’s efficacy is
improved in the absence of RAMP3, this may play a role
in the differential effects in rats versus mice. Even though
acute sCT produces an anorectic effect in mice and rats
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(Coester et al., 2019), we could also hypothesize that in a
subchronic setting, CTR transcription or transport is
differentially regulated between mice and rats or that
activation of downstream pathways may be different
between species leading to this resistance and absence of
effect in mice.
As briefly mentioned above, we have previously
identified that in the C57Bl6 background mouse AP
(Coester et al., 2020), CTRa is mostly colocalized with
RAMP3 compared to RAMP1. In the ARC, RAMP1 and
RAMP3 are equally colocalized with CTR albeit at a
lesser density than in the AP. However, in the ARC and
AP, RAMP3 seems more abundant than RAMP1 (Coester
et al., 2020). However, in the mice on a 129S2/SvEv
background, RAMP2 seems to be most abundant and the
preferred associated RAMP subunit to CTR in the
AP. For comparison, in the rat AP, at the single-cell level,
CTRa+ neurons are colocalized with RAMP1 (3%),
RAMP3 (10%) and RAMP1/3 (25%) (Liberini et al., 2016).
Furthermore, the metabolic characterization of these
RAMP KO mice models suggests that AMY3 is more rele-
vant for eating effects and AMY1 for adiposity (Coester
et al., 2019). Thus, although the present study sheds some
light on the specific role of RAMP in mediating the effect
of DACRA and amylin selective analogue, further studies
need to be conducted to investigate the role and the exact
expression of AMY1–3 in mice to properly understand
their mechanism of action in mouse models. If one
RAMP is knocked out, we may expect the other two to be
overexpressed. On the basis of this concept, we may
expect that RAMP3 KO mice showed an overexpression
of RAMP1 and RAMP2 to compensate the loss of func-
tion of RAMP3. Opposite to our expectation, however, we
here showed that the depletion of one or two RAMPs
(in a 129S2/SvEv background mouse) decreases the
transcription of the other RAMPs. Furthermore, it seems
that RAMP3 plays a crucial role because its absence may
prevent the colocalization of the RAMP1 or RAMP2
with CTR.
The role of RAMP2 that forms AMY2 when combined
to CTR (Morfis et al., 2008; Tilakaratne et al., 2000), in
mediating amylin-related signals, is poorly investigated.
Unlike RAMP1 and RAMP3 KO mouse models that
survive during embryonic development, RAMP2 KO mice
are lethal embryonically, showing generalized edema
(Kadmiel et al., 2012). Several studies demonstrated that
RAMP2 is essential for angiogenesis and for the
development and integrity of a functional lymphatic
system (Dackor et al., 2007; Fritz-Six et al., 2008;
Ichikawa-Shindo et al., 2008). These findings indicate
that endogenous expression of RAMP1 and RAMP3 is
not able to compensate for the physiological function of
RAMP2. In contrast, global deletion of either RAMP1 or
RAMP3 does not affect survival, perhaps because the
expression of other RAMPs and particularly RAMP2 is
able to compensate for their absence and their loss of
function. At present, we do not know whether some
effects observed in this study can be explained by amylin
agonist or DACRA action at the AMY2 receptor, that is,
whether there is a pharmacological role of AMY2 in the
control of food intake and body weight when interacting
with amylin, amylin agonists and DACRAs. In the rat
AP, RAMP2 is present in amylin-induced cFos+ neurons
and is upregulated after acute amylin, whereas RAMP1
and RAMP3 are downregulated (Liberini et al., 2016).
4.1 | Limitation of the study
RAMP can dimerize with either CTR to form the amylin
receptors 1–3 or with the calcitonin receptor-like receptor
(CLR). CLR/RAMP1 is considered as the primary
CGRP receptor. CLR/RAMP2 and CLR/RAMP3 are the
adrenomedullin 1 and 2 receptors (Lee et al., 2016).
Amylin receptors 1 and 3 can also bind CGRP, and
AMY1 is considered as the second CGRP receptor.
Together, RAMP, CLR and CTR generate at least seven
pharmacologically distinct receptors (not including splice
variants) making the study of these signalling pathway
quite arduous (Boccia et al., 2020; Lee et al., 2016;
Lorenzen et al., 2019). Thus, whole-body RAMP KO ani-
mal models assess diverse metabolic functions that are
not limited to only amylin-related signalling. Further-
more, our in situ hybridization colocalization should be
interpreted carefully because we showed the localization
of CTR and the different RAMPs at the mRNA
level. Whether this is reflected at the protein level
remains unknown due to the absence of specific RAMP
antibodies. Furthermore, the presence of CTR and
RAMPs mRNA within one cell does not guarantee that
these two components form a functional receptor
subunit. Finally, given the sex difference we previously
observed in regard to their metabolism (Coester
et al., 2019) and given that obesity is as prevalent in men
and women, testing the anorectic effect of NN1213 in
female mice may be necessary in the future to fully
validate new pharmaceutical drugs.
4.2 | Conclusion
Together these studies highlight the crucial role of AMY3
in mediating DACRA and selective amylin receptor
agonist weight lowering effect in mice, albeit in opposite
directions. They also emphasize that these compounds
may produce species-specific effects that need to be
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further investigated. Indeed, these results indicate the
need to test preclinical compounds in multiple species
and whether negative effects in one species may preclude
the absence of effect in a clinical study remains to be fur-
ther investigated.
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